Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NWnwV5dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTNSHJKSzVyPUWuPFY3PiEQvF2= MXvTRW5ITVJ?
DOHH-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvuTWM2OD17LkO1Olg6KM7:TR?= MXXTRW5ITVJ?
no-10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTzTWM2OD17LkmwN|kh|ryP M4fNfHNCVkeHUh?=
LS-513 NFfSeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;kXFNKSzVyPUGxMlM2PDdizszN MYDTRW5ITVJ?
ALL-PO MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDGTWM2OD1zMT63O|M1KM7:TR?= MmTMV2FPT0WU
8-MG-BA M1rN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm5TWM2OD1zMz6xNVI{KM7:TR?= NUjjT3Q3W0GQR1XS
RPMI-8402 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPOToNKSzVyPUG1Mlg2OzdizszN MlXEV2FPT0WU
EoL-1-cell MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vaXWlEPTB;MUiuOVk1QCEQvF2= M2m2UXNCVkeHUh?=
NALM-6 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e0WGlEPTB;MUmuNFE3PyEQvF2= MlrOV2FPT0WU
DEL MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HUVmlEPTB;MkCuNVQ4OSEQvF2= MUjTRW5ITVJ?
SR NIeyXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLV[mxKSzVyPUKzMlY4OTVizszN M3PqUXNCVkeHUh?=
697 NWf3SmFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfJRVNKUUN3ME2yOk43OTV3IN88US=> MorJV2FPT0WU
COLO-829 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ4Lki0PFMh|ryP NXXjeYR4W0GQR1XS
EVSA-T NFP6U5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\lcJlKSzVyPUK3MlU2PjFizszN MX\TRW5ITVJ?
ATN-1 NEnO[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrSXXUzUUN3ME2zNU4zOzJ7IN88US=> NGqwOJlUSU6JRWK=
L-363 NITXbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7kTWM2OD1|MT63OFYyKM7:TR?= MoTZV2FPT0WU
LAMA-84 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTN{LkWyNVEh|ryP MWPTRW5ITVJ?
NOS-1 NEnSelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTN2LkK5OVYh|ryP M{\ifnNCVkeHUh?=
BB30-HNC Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO2bIJFUUN3ME2zOE4{OzB4IN88US=> MYjTRW5ITVJ?
BC-1 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[yVWlEPTB;M{euPVc1PiEQvF2= MX3TRW5ITVJ?
IST-SL2 M2LL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTN6LkKyOEDPxE1? NF7RR4dUSU6JRWK=
D-392MG MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT5ZWpKSzVyPUSwMlIzOTVizszN NVH0U5dtW0GQR1XS
no-11 NV[xSXhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTRyLkW1NlEh|ryP MU\TRW5ITVJ?
LC4-1 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILVWpFKSzVyPUSwMlg4OTZizszN MUPTRW5ITVJ?
A388 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jYcmlEPTB;NEKuOVg1QCEQvF2= NEXTfIZUSU6JRWK=
NTERA-S-cl-D1 M1\icWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTR{LkewO|Qh|ryP NX\RSFd7W0GQR1XS
CESS MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjieFRVUUN3ME20OE4zOjN{IN88US=> NVPYNG5GW0GQR1XS
RS4-11 M2f0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXKTHFKSzVyPUS5MlA6OzhizszN NWqxUFJwW0GQR1XS
MS-1 NFHmfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nBO2lEPTB;NUCuPVM2OSEQvF2= MWLTRW5ITVJ?
CTV-1 M2TpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvjdIoxUUN3ME21NU4xPzRizszN NWDzXFZkW0GQR1XS
D-502MG MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrFTWM2OD13MT62NlcyKM7:TR?= NY\lZXlYW0GQR1XS
ML-2 NH;UVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;xWW1kUUN3ME21Nk46OTl3IN88US=> NHXVVFVUSU6JRWK=
SK-NEP-1 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnv[5FRUUN3ME21N{4{QTJ|IN88US=> MnW2V2FPT0WU
LOXIMVI MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[wRmlEPTB;NUOuOVg5PCEQvF2= NFfvVlBUSU6JRWK=
DJM-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m4W2lEPTB;NU[uN|M6OSEQvF2= MWHTRW5ITVJ?
GI-1 MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfJeXVpUUN3ME21Ok43OTR7IN88US=> M1LXRXNCVkeHUh?=
IST-MES1 MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZyLkW0PVMh|ryP NWK0T4JLW0GQR1XS
MV-4-11 M4HDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTZyLk[1N|gh|ryP NXiwbZN{W0GQR1XS
OVCAR-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PiTGlEPTB;NkOuOVY2PyEQvF2= NV3EelU1W0GQR1XS
KE-37 MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlztTWM2OD14Nj6yOlY5KM7:TR?= M4PLS3NCVkeHUh?=
D-542MG NV\rS|Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYniVpNXUUN3ME22PE41OTN3IN88US=> MVzTRW5ITVJ?
MHH-PREB-1 NWfQdGk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP6TmZKSzVyPUeyMlg1PDFizszN NFPwOYFUSU6JRWK=
MRK-nu-1 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPKRm5KSzVyPUezMlQ4ODVizszN M3vzZnNCVkeHUh?=
D-247MG NEPJPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTd|LkW0OFIh|ryP MoDKV2FPT0WU
OCI-AML2 NIrIbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILjSmtKSzVyPUe2Mlk{PjlizszN NU\hW2h3W0GQR1XS
LP-1 MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[1TWM2OD16Mj64O|MyKM7:TR?= MnHwV2FPT0WU
HCC1599 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\acJFKSzVyPUi0MlI5OzdizszN M4n5eHNCVkeHUh?=
KARPAS-45 NGXnZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHBR4RHUUN3ME24OE43QTl{IN88US=> NHnWSZdUSU6JRWK=
BE-13 NVrCUlFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnLN21HUUN3ME25PU4xPDd5IN88US=> NUfVOYR1W0GQR1XS
GCIY MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPTbJR3UUN3ME25PU4xQTV2IN88US=> NWjWe5NsW0GQR1XS
BV-173 NHfLd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PSdWlEPTB;MUCwMlMzPSEQvF2= MXjTRW5ITVJ?
LB2518-MEL Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvYZopKSzVyPUGwNE44QDlizszN M1PaN3NCVkeHUh?=
KS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17rSWlEPTB;MUCxMlY{QSEQvF2= NXmzTolnW0GQR1XS
MOLT-16 M1r0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfoTWM2OD1zMESuPVg3KM7:TR?= NWrNWllxW0GQR1XS
NCI-H1770 MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7kSnhKSzVyPUGwPE44QDRizszN M2HUW3NCVkeHUh?=
NCI-H82 NV7XRo8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LKNmlEPTB;MUGwMlk4PiEQvF2= M3jxNXNCVkeHUh?=
NCCIT NV7RZVV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP5TWM2OD1zMUKuOVI6KM7:TR?= NWnNZXV4W0GQR1XS
KALS-1 NYr3TJp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;NemlEPTB;MUG1Mlk1OSEQvF2= MYLTRW5ITVJ?
LB2241-RCC NH7sc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e0c2lEPTB;MUG2MlY4QSEQvF2= NXfvXmlNW0GQR1XS
HH NV3BRnBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fJXWlEPTB;MUG3MlM6PSEQvF2= NU\pVW1NW0GQR1XS
HD-MY-Z M4HjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrCUIxKSzVyPUGxPE41QDhizszN M1HnfXNCVkeHUh?=
EB-3 M4[3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTHR2FZUUN3ME2xNlMvODl2IN88US=> MonCV2FPT0WU
BL-70 NWnWNY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF{Mz6xNlch|ryP MYnTRW5ITVJ?
K-562 M1Ti[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rxXGlEPTB;MUK2MlI1PSEQvF2= NVmwVIxiW0GQR1XS
HT-144 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PLeGlEPTB;MUOzMlE3PCEQvF2= MV7TRW5ITVJ?
PF-382 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnxXWlKSzVyPUGzOE4{PjFizszN NWPoR2xZW0GQR1XS
RPMI-8226 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom1TWM2OD1zM{WuNFQ2KM7:TR?= MVHTRW5ITVJ?
NCI-H1355 MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXNTWM2OD1zM{WuOVg4KM7:TR?= M3zGVXNCVkeHUh?=
LXF-289 NYWz[GZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF|OT63PFEh|ryP Mlq3V2FPT0WU
NCI-H69 NInyVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\nTWM2OD1zNEKuPVMzKM7:TR?= MUXTRW5ITVJ?
SK-MEL-1 NXTXe|VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF2Nz6xN{DPxE1? MV7TRW5ITVJ?
KARPAS-299 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z6RmlEPTB;MUS5MlEzKM7:TR?= NELneVVUSU6JRWK=
GB-1 NWHMT3I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF2OT6zNlIh|ryP MYfTRW5ITVJ?
CMK MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW2VoNrUUN3ME2xOFkvPTF3IN88US=> NXrpXVJYW0GQR1XS
MPP-89 NV34TG16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF3Nj6wN|Uh|ryP MX;TRW5ITVJ?
KU812 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPl[G05UUN3ME2xOlEvQTB{IN88US=> MWTTRW5ITVJ?
REH MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfEZnlKSzVyPUG2Nk4yOjVizszN MXvTRW5ITVJ?
NEC8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPEOpNJUUN3ME2xOlUvODJ4IN88US=> M4fEPHNCVkeHUh?=
KP-N-YS NVHI[5N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nac2lEPTB;MU[4MlM6PSEQvF2= MkXIV2FPT0WU
Ramos-2G6-4C10 M3jndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTJWnVLUUN3ME2xOlkvQTF3IN88US=> M4qySnNCVkeHUh?=
Becker MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF5ND6xPEDPxE1? MXXTRW5ITVJ?
LB647-SCLC MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXNTWM2OD1zN{WuPFQ2KM7:TR?= M2mzVnNCVkeHUh?=
LU-139 M1e0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHXO3FWUUN3ME2xO|gvODF7IN88US=> NWLJ[HU6W0GQR1XS
QIMR-WIL NYmwdllqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF5OT62OFYh|ryP MV;TRW5ITVJ?
NCI-H1395 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF5OT65PVYh|ryP NYHofm5XW0GQR1XS
NOMO-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[2TWM2OD1zOEKuPFUh|ryP NIi5fXNUSU6JRWK=
GI-ME-N NWraTZp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HkWmlEPTB;MUi3Mlk3QSEQvF2= NUDUfHNuW0GQR1XS
KMS-12-PE MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHReI9KSzVyPUG4PU4zPzNizszN NGK5cJJUSU6JRWK=
Daudi NVn3[VE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTCO3ZGUUN3ME2xPVEvOTJ6IN88US=> Ml3kV2FPT0WU
LB996-RCC NGnCUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DMbmlEPTB;MUmxMlY6QSEQvF2= NWrPSY83W0GQR1XS
NCI-H2107 NFjZTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHNdVRKSzVyPUG5N{44OzlizszN NF\BOopUSU6JRWK=
SK-PN-DW NEDMUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDXbmRKSzVyPUG5OE44OTlizszN NFLkWXNUSU6JRWK=
MC-CAR NYPFVlBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HOdWlEPTB;MkCyMlI2OyEQvF2= M{PFXnNCVkeHUh?=
SNB75 NWO3T2pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzPTWM2OD1{MkGuPVQh|ryP MWfTRW5ITVJ?
ES4 M4HYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD2fo1vUUN3ME2yNlMvPzh|IN88US=> MkjRV2FPT0WU
KARPAS-422 Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJ{OD6zOVIh|ryP MmL6V2FPT0WU
NCI-H1648 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfhTWM2OD1{MkmuOFg6KM7:TR?= MV3TRW5ITVJ?
ES6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ITWM2OD1{M{muOFMh|ryP NHO3PW9USU6JRWK=
KNS-81-FD NFLJTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJ2MT6xPVch|ryP NHrTNpFUSU6JRWK=
JAR NV20cIVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLiNYFKSzVyPUK1Ok4zOjVizszN NF;BXJhUSU6JRWK=
NB1 M4jaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX4OYpKSzVyPUK2NE42OTZizszN Mn3GV2FPT0WU
D-336MG MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ4MD62PVgh|ryP MVfTRW5ITVJ?
BC-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT3TWM2OD1{NkWuNVc5KM7:TR?= Mm\GV2FPT0WU
HCC2218 M3TpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ4Nj60NVUh|ryP MYrTRW5ITVJ?
TE-9 NXHhfGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJ4Nj62Nlch|ryP MmG1V2FPT0WU
LB1047-RCC M1vhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj2TWM2OD1{Nk[uO|U{KM7:TR?= MnjiV2FPT0WU
CTB-1 NHfqPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSyRnZKSzVyPUK2PU46PzNizszN NXrpeINFW0GQR1XS
NB7 NEHIdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\NTWM2OD1{N{Gg{txO NIrqfZFUSU6JRWK=
ST486 NGe3ZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTDTWM2OD1{N{euOFEzKM7:TR?= NVzpW2hUW0GQR1XS
HCC1187 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLCTWM2OD1{OEKuPFEyKM7:TR?= NF;BdI5USU6JRWK=
NCI-SNU-16 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnOTWM2OD1{OESuNlQ5KM7:TR?= NHPDepdUSU6JRWK=
COR-L279 NFi1XXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT4TWM2OD1{OUGuOVg1KM7:TR?= MU\TRW5ITVJ?
ES8 NX;S[2NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ7ND6xPFIh|ryP MmjiV2FPT0WU
U-698-M MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v4RWlEPTB;Mkm4MlI1OyEQvF2= NEK0eZBUSU6JRWK=
HEL NGXEdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHpSnA5UUN3ME2zNFkvOTR7IN88US=> NWLST4J2W0GQR1XS
KINGS-1 NHXSZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrDXVVKSzVyPUOxNE43PzRizszN NH3KRWtUSU6JRWK=
KY821 NHrMPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN|Nj61PVUh|ryP NELyXIZUSU6JRWK=
MZ1-PC M3exOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPBNoRKSzVyPUO0OU43OThizszN M{LZ[nNCVkeHUh?=
LS-411N MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[xZ4hKSzVyPUO1OE43PiEQvF2= MnHTV2FPT0WU
SIG-M5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[2V2lEPTB;M{W5Mlc5OiEQvF2= M2n3bnNCVkeHUh?=
HT MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TOcmlEPTB;M{[3MlcyOSEQvF2= NFPwcXRUSU6JRWK=
HC-1 NHTORpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXQTWM2OD1|NkeuO|g4KM7:TR?= NFWwb3BUSU6JRWK=
NCI-H1694 M2m3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXPXXNKSzVyPUO3Nk46OzRizszN NXPSXmJyW0GQR1XS
BB65-RCC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\6RldKSzVyPUO3Ok4zPDVizszN MlzFV2FPT0WU
HAL-01 NH\t[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW4cWVKSzVyPUO3PU45OzhizszN M1:0UnNCVkeHUh?=
ARH-77 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\iTWM2OD1|OUSuNFA5KM7:TR?= MnrkV2FPT0WU
MZ7-mel M3K2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHqTIRFUUN3ME2zPVcvOjN|IN88US=> M{DYdnNCVkeHUh?=
SIMA MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rJOWlEPTB;NECzMlk{OyEQvF2= NVLZVphMW0GQR1XS
DG-75 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTRzNT62PVgh|ryP MWrTRW5ITVJ?
HUTU-80 NIT1SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7rfGFWUUN3ME20NVkvOTh3IN88US=> NXHqXJl[W0GQR1XS
KNS-42 NF63b4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL6dG5KSzVyPUSyOU45OTVizszN NV\RPYhlW0GQR1XS
SH-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTR{Nz61OlUh|ryP MXLTRW5ITVJ?
L-540 NWraSFFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q5PWlEPTB;NEOxMlA{OSEQvF2= NV3nWJhpW0GQR1XS
NB10 NHnaVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3GXoZKSzVyPUS0NU4zOzRizszN Mn3HV2FPT0WU
ES1 MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\pPGlEPTB;NEWyMlc2OyEQvF2= MnflV2FPT0WU
KMOE-2 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\t[GlEPTB;NEW2MlcyOSEQvF2= NYrHcJM2W0GQR1XS
MC116 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnhTWM2OD12NUiuNVE3KM7:TR?= NFy2TFVUSU6JRWK=
RCC10RGB M2jCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrQd|VNUUN3ME20OlAvODB3IN88US=> NYDWTVl1W0GQR1XS
RL95-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G4emlEPTB;NE[wMlI{PyEQvF2= NFPWUG9USU6JRWK=
Raji MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR4OD6xOFMh|ryP NIPSVXBUSU6JRWK=
CAS-1 NYDoenBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DKe2lEPTB;NEeyMlA4OyEQvF2= NXjk[2dGW0GQR1XS
Calu-6 NWD6Nm1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR5NT6yOlUh|ryP MmG3V2FPT0WU
KG-1 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTR5OD60OEDPxE1? MnO2V2FPT0WU
LB771-HNC NIDFTWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zoVmlEPTB;NEiyMlI{OiEQvF2= MlvQV2FPT0WU
ACN MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn73TWM2OD12OUOuOVk6KM7:TR?= MULTRW5ITVJ?
KM12 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7ObpBlUUN3ME20PVYvPTh7IN88US=> MWnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID